German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients

AIDS Research and Therapy

Volumn 11, Issue 1, 2014, Pages

  Beisel, Claudia ^a   Heuer, Martin ^a   Otto, Benjamin ^a   Jochum, Johannes ^a   Schmiedel, Stefan ^a   Hertling, Sandra ^a   Degen, Olaf ^a   Lüth, Stefan ^a   van Lunzen, Jan ^a   Schulze zur Wiesch, Julian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

HCV HIV co infection; Hepatitis C; PEG interferon ribavirin treatment

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN; HEMOGLOBIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; GERMANY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

EID: 84904022420     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-11-16     Document Type: Article

References (34)

1. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, Michelet C, Pol S, Perronne C, Cacoub P. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007, 14:183-188.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492-497.
3. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003, 38:257-265.
4. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellon JM, Gonzalez-Garcia J. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009, 50:407-413.
5. Lindh M, Arnholm B, Eilard A, Farkkila M, Hellstrand K, Lagging M, Langeland N, Morch K, Nilsson S, Pedersen C, Buhl MR, Wahlberg T, Wejstal R, Westin J, Norkrans G. Hepatitis C treatment response kinetics and impact of baseline predictors. J Viral Hepat 2011, 18:400-407.
6. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-651.
7. Schulze Zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse AW, Luth S. " Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus. Hepatology 2011, 53:1405-1406. author reply 1407.
8. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
10. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007, 14:239-248.
11. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Jr Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
13. Nunez M, Marino A, Miralles C, Berdun MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007, 45:439-444.
14. Jalali Z, Rockstroh JK. Antiviral drugs and the treatment of hepatitis C. Curr HIV/AIDS Rep 2012, 9:132-138.
15. Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schurmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Golz J, Staszewski S, Rockstroh JK. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. Eur J Med Res 2010, 15:102-111.
16. Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int 2013, 33(Suppl 1):63-67.
17. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all?. Nat Rev Drug Discov 2013, 12:595-610.
18. Sulkowski MS, Rodriguez-Torres M, Lalezari J, Fessel WJ, Mounzer K, Shuhart M. All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1). Hepatology 2013, 58(suppl):313A.
19. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren J, Rockstroh J, Kirk O, Mocroft A. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med 2013, 14(10):614-623.
20. Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005, 40(Suppl 5):S349-S354.
21. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
22. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004, 11:243-250.
23. AIDS definition update by CDC. Am Fam Physician 1993, 47:265.
24. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A, Christensen S, Koppe S, Kundi M, Rieger A, Peck-Radosavljevic M. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011, 16:815-824.
25. Blackard JT, Sherman KE. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver?. J Viral Hepat 2008, 15:323-330.
26. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16:813-828.
27. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Piratvisuth T, Marcellin P, Fried MW. A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. Hepatology 2013, 57(4):1325-1332.
28. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
29. Schulze Zur Wiesch J, Lohse AW. Results of the IDEAL trial: " Mirror, mirror on the wall .. which's the fairest peg-interferon of them all?" . Hepatology 2009, 50:2034-2037.
30. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
31. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
32. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Brau N, Hatzakis A, Pol S, Rockstroh J. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007, 21:1073-1089.
33. Valerio L, Yazdanpanah Y, Poizot-Martin I, Rosenthal E, Marimoutou C, Gastaut JA, Tran A, Dellamonica P, Freedberg KA, Pradier C. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2008, 47:50-55.
34. Sulowski M. Hepatitis C virus-human immunodeficiency virus coinfection. Liver Int 2012, 32(Suppl 1):129-134.